(redirected from elan)
Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
See: ardor
Mentioned in ?
References in periodicals archive ?
NanoCrystal(R) Technology is a registered trademark owned by Elan Pharma International Limited Corporation, Ireland.
Included in the Elan/DDSI license agreement is a loan agreement which provides for Elan to make a seven-year, $10 million loan to DDSI to further develop the three DDSI Dryhaler compounds currently under development (albuterol, beclomethasone and bitolterol).
Garner stated that a future collaboration between Dura and Elan would be an especially strong fit given their respective strengths.
Panoz, Chairman and Chief Executive Officer of Elan Corporation, 353/9025-94666/
Elan is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing, selling and marketing advanced therapies in neurodegenerative diseases, autoimmune diseases and severe pain.
The reorganization is designed to handle the growth in the worldwide operations of Elan which have occurred since 1987 and to ensure that we have a management structure which can guide the company through its next phase of growth and capitalize on the many opportunities that are available to us.
Planella continued "working in partnership with a company of the calibre of Elan is an important and welcome development for Vita.
As a leading partner to financial institutions, Elan is dedicated to providing the best possible credit card program," said Dan Roads, first vice president of Elan Financial Services, based in Milwaukee.
The board of Elan also today announced the appointment of Joseph McCabe as director of the company.
E) recently established through a successful Elan Corporation, plc.
DUBLIN, Ireland & TORONTO -- Elan Corporation, plc ("Elan") (NYSE:ELN) and Transition Therapeutics Inc.
Elan currently has numerous development agreements with Japanese companies, four of which now involve the marketing of products in Japan by its valued licensees in Japan -- Tanabe Seiyaku, SS Pharmaceuticals and Mitsubishi Kasei -- and such agreements and similar development agreements in the future are unaffected by the formation of the joint venture.